Investing in Rare Disease Patient Advocacy Groups

Patient advocacy groups (PAGs) excel in bringing together multiple stakeholders – KOLs, physicians, caregivers, policy makers, and patients – throughout development. Close involvement with PAGs helps pharmaceutical and biotech companies advance therapeutics more easily and often more rapidly through the development cycle and regulatory approval process.

Investing early in PAGs’ success is a sound strategic move that may increase a company’s chances of success by forming a collaboration that enhances patient access and embraces advocacy as this team works together toward compatible goals.